NUDT13 antibodies are polyclonal reagents designed to target the Nudix Hydrolase 13 protein (UniProt ID: Q86X67), which hydrolyzes reduced pyridine nucleotides like NADH and NADPH . These antibodies are validated for applications including:
Western Blot (WB)
Immunohistochemistry (IHC)
Enzyme-Linked Immunosorbent Assay (ELISA)
Key suppliers include Thermo Fisher Scientific (PA5-59234), Proteintech (25912-1-AP), and Abcepta (AI12941) .
Molecular Weight: ~40 kDa (calculated), observed at 30–40 kDa due to post-translational modifications .
Immunogen Sequence: QDAQRIEDSVLIGCSEQQEAWFALDLGLDSSFSISASLHKPEMETELKGSFIELRKALFQLNARDASLLSTAQALLRWH .
| Substrate | Activity | Product(s) |
|---|---|---|
| NADH | High | NMNH + AMP |
| NADPH | Moderate | NMNH + 2′,5′-ADP |
| Other NTPs | Low | Not applicable |
Data derived from recombinant mouse Nudt13 assays .
NUDT13 is targeted to mitochondria via an N-terminal peptide, as shown by GFP fusion experiments in HeLa cells .
Co-localizes with Mitotracker Red, confirming mitochondrial matrix activity .
Expression in Tumors: Elevated in colorectal, breast, and lung cancers (Human Protein Atlas) .
Functional Impact: siRNA knockdown of NUDT13 reduces viability in non-cancer colon epithelial cells (CCD841) but not in cancer cell lines (A549, MCF7) .
| Application | Dilution Range |
|---|---|
| Western Blot | 1:500–1:2000 |
| IHC | Titration required |
Data compiled from Thermo Fisher, Proteintech, and Abcepta protocols .
NUDT13 antibodies are critical for: